U.S. markets closed

Sotera Health Company (SHC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.84-0.02 (-0.08%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Sotera Health Announces Pricing of Secondary Offering
    GlobeNewswire

    Sotera Health Announces Pricing of Secondary Offering

    CLEVELAND, March 17, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the pricing of its secondary offering (the “Offering”) of 25,000,000 shares of its common stock at a price to the public of $27.00 per share. All 25,000,000 shares are being offered by selling stockholders, which include certain affiliates of Warburg Pincus LLC and GTCR, LLC, as well as certain current and former members of management of the Company. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of common stock. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company has agreed to pay certain Offering expenses consistent with its obligations under its Amended and Restated Registration Rights Agreement. The Offering is expected to close on March 22, 2021, subject to customary closing conditions. J.P. Morgan, Credit Suisse, Goldman Sachs & Co. LLC and Jefferies are acting as joint lead book-running managers and as representatives of the underwriters for the Offering. Barclays, Citigroup and RBC Capital Markets are acting as joint book-running managers for the Offering. BNP PARIBAS, KeyBanc Capital Markets, Citizens Capital Markets, ING, Academy Securities, Loop Capital Markets, Penserra Securities LLC, Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the Offering. The Offering is being made only by means of a prospectus. Copies of the final prospectus relating to the Offering may be obtained, when available, from: J.P. Morgan Securities, LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; Credit Suisse Securities (USA), LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at usa.prospectus@credit-suisse.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone 1-866- 471-2526 or by email at Prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone 1-877-821-7388 or by email at Prospectus_Department@Jefferies.com. A registration statement relating to these securities was declared effective as of March 17, 2021 by the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-looking Statements: Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company’s registration statement on Form S-1 filed with the SEC, including under the headings of “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement and under the headings of “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law. About Sotera Health: Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®. INVESTOR RELATIONS CONTACTS: Sally J. Curley, IRC Jenny KobinCurley Global IR, LLCIR Advisory SolutionsIR@soterahealth.com IR@soterahealth.com MEDIA CONTACT: Kristin Gibbs Chief Marketing Officer, Sotera Health kgibbs@soterahealth.com Source: Sotera Health Company

  • Sotera Health Announces Secondary Offering of Common Stock
    GlobeNewswire

    Sotera Health Announces Secondary Offering of Common Stock

    CLEVELAND, March 15, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered by selling stockholders, which include certain affiliates of Warburg Pincus LLC and GTCR, LLC, as well as certain current and former members of management of the Company. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of common stock. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company has agreed to pay certain Offering expenses consistent with its obligations under its Amended and Restated Registration Rights Agreement. The Company also announced that, in connection with the Offering, J.P. Morgan Securities LLC, the representative of the several underwriters in the Company’s initial public offering of common stock completed in November 2020, is waiving a lock-up restriction with respect to shares of the Company’s common stock held by certain officers and other stockholders of the Company. The Company also announced that it plans to seek an amendment to its existing credit agreement with the objective of obtaining more favorable pricing and extending the maturity on its revolving credit facility, which is currently undrawn. There can be no assurance that the Company will be successful in obtaining such an amendment, which will depend on market conditions and other factors which are subject to change. J.P. Morgan, Credit Suisse, Goldman Sachs & Co. LLC and Jefferies are acting as joint lead book-running managers and as representatives of the underwriters for the Offering. Barclays, Citigroup and RBC Capital Markets are acting as joint book-running managers for the Offering. BNP PARIBAS, KeyBanc Capital Markets, Citizens Capital Markets, ING, Academy Securities, Loop Capital Markets, Penserra Securities LLC, Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the Offering. The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the Offering may be obtained, when available, from: J.P. Morgan Securities, LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; Credit Suisse Securities (USA), LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at usa.prospectus@credit-suisse.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone 1-866-471-2526 or by email at Prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone 1-877-821-7388 or by email at Prospectus_Department@Jefferies.com. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-looking Statements: Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company's registration statement on Form S-1 filed with the SEC, including under the headings of “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement and under the headings of “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law. About Sotera Health: Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®. INVESTOR RELATIONS CONTACTS: Sally J. Curley, IRC Jenny KobinCurley Global IR, LLCIR Advisory SolutionsIR@soterahealth.com IR@soterahealth.com MEDIA CONTACT: Kristin Gibbs Chief Marketing Officer, Sotera Health kgibbs@soterahealth.com Source: Sotera Health Company

  • Sterigenics Announces Expansion of Rantigny Facility to Increase European Sterilization Capacity
    GlobeNewswire

    Sterigenics Announces Expansion of Rantigny Facility to Increase European Sterilization Capacity

    OAK BROOK, IL, March 10, 2021 (GLOBE NEWSWIRE) -- Sterigenics S.A.S., a subsidiary of Sotera Health and a global leader in comprehensive sterilization services, announces the expansion of its ethylene oxide (EO) facility located in Rantigny, France to increase European sterilization capacity. The expansion increases the Rantigny facility’s total sterilization throughput and diversifies its capabilities with the addition of a 32-pallet chamber. “Local and regional demand for contract sterilization services has been increasing to meet healthcare needs,” said Pontus Rundstrom, Vice President, Operations EMEAA. “The additional capacity at Rantigny shows our commitment to our sterilization customers by helping to get their products into the market in a fast, flexible and reliable way.” Sterigenics remains committed to addressing the growing need for sterilization in many parts of the world. The Sterigenics’ Rantigny facility provides routine EO, EOStat® rapid processing, cycle development and process validation and offers laboratory testing services through its co-located Nelson Labs facility. The Rantigny expansion follows Sterigenics’ recent acquisition of Iotron Industries, a leading electron beam provider in North America. The acquisition further expands the company’s capacity across multiple technologies throughout its global network. About Sotera Health: Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®. About Sterigenics: Sterigenics is a leading global provider of outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. With our industry recognized scientific and technological expertise we help to ensure the safety of millions of patients and healthcare practitioners around the world every year. Across our 48 facilities worldwide, we offer our customers a complete range of outsourced terminal sterilization services, primarily using the three major sterilization technologies: gamma irradiation, ethylene oxide processing and electron beam irradiation and expert advisory services. We are committed to addressing the growing need for sterilization in many parts of the world and partnering with our customers to eliminate threats to human health. Safeguarding Global Health® - with every product we sterilize. About Nelson Labs: Nelson Labs is a global leader in outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. Nelson Labs serves over 3,800 customers across 14 facilities in the United States, Mexico, Asia and Europe. We have a comprehensive array of over 800 laboratory tests supporting our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance. We are regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. Safeguarding Global Health® - with every test we complete. Media ContactSOTERA HEALTH and STERIGENICS:Kristin GibbsChief Marketing Officerkgibbs@soterahealth.com